FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

31 results

crestor
(Rosuvastatin)
AstraZeneca Pharmaceuticals LP
Usage: CRESTOR is indicated for reducing the risk of major cardiovascular events in adults at increased risk, as an adjunct to diet for lowering LDL cholesterol in various hyperlipidemias, and for treating primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It is also used in pediatric patients with familial hypercholesterolemia.
ezallor sprinkle
(ROSUVASTATIN)
Sun Pharmaceutical Industries, Inc.
Usage: EZALLOR SPRINKLE is indicated to reduce the risk of major adverse cardiovascular events in at-risk adults, lower LDL cholesterol in various hyperlipidemia types, and treat primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It can be used alone or with other LDL-lowering therapies for patients with familial hypercholesterolemia.
liraglutide
(liraglutide)
Teva Pharmaceuticals USA, Inc.
Usage: Liraglutide is indicated for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes, and reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is not for use in type 1 diabetes patients.
lodoco
(Colchicine Tablets 0.5 mg)
AGEPHA Pharma USA, LLC
Usage: LODOCO is indicated for reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular disease risk factors.
nexletol
(Bempedoic Acid)
Esperion Therapeutics, Inc.
Usage: NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.
nexlizet
(Bempedoic Acid and Ezetimibe)
Esperion Therapeutics, Inc.
Usage: NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated as an adjunct to diet for reducing LDL-C in adults with primary hyperlipidemia, including HeFH. Bempedoic acid also lowers myocardial infarction and coronary revascularization risk in adults unable to take statins, with or without established cardiovascular disease.
ozempic
(semaglutide)
Novo Nordisk
Usage: OZEMPIC is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. It also reduces the risk of major adverse cardiovascular events and helps in preventing kidney disease progression in patients with type 2 diabetes and chronic kidney disease.
praluent
(alirocumab)
Regeneron Pharmaceuticals, Inc.
Usage: PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.
ramipril
(Ramipril)
Hikma Pharmaceuticals USA Inc.
Usage: Ramipril is indicated for treating hypertension, reducing cardiovascular event risks such as myocardial infarction and stroke. It is also used in high-risk patients over 55 to lower cardiovascular event risks and in stable patients post-myocardial infarction to decrease mortality and heart failure progression.
repatha
(Evolocumab)
Amgen USA Inc.
Usage: REPATHA is indicated for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and as an adjunct to diet and other therapies to lower LDL cholesterol in adults and pediatric patients (ages 10+) with primary hyperlipidemia, heterozygous, or homozygous familial hypercholesterolemia.

Medications for Cardiovascular Diseases

crestor

ezallor sprinkle

liraglutide

lodoco

nexletol

nexlizet

ozempic

praluent

ramipril

repatha